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MCO formulary managers for a migraine treatment that
has a good chance of relieving pain within 15 minutes,
allowing quick return to normal activities. We also found
that patients and physicians are willing to pay much more
than MCO formulary managers for other quality-of-life
beneﬁts, including preferred dosage form, nausea relief
and avoiding drowsiness.
CONCLUSIONS: The results support our hypothesis that
physicians and patients value quality-of-life beneﬁts more
highly than MCO formulary managers. However, the
sample sizes involved are too small to permit strong 
inference.
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Despite insomnia induces a great number of medical and
psychiatric visits, the role of co-morbidity in the medical
and professional consequences of this sleep disorder is
poorly documented.
OBJECTIVES: Our study seeks to evaluate the impact of
insomnia on the health status and absenteeism; and 
to identify the part of co-morbidity in the severity of
insomnia.
METHODS: We used data from the Gazel cohort (a
cohort of employees of the French electrical and gas
company) providing medical, professional and demo-
graphic information; the Epworth sleepiness scale; the
Nottingham Health Proﬁle; the Basic Nordic Sleep Ques-
tionnaire and a 3-week sleep log. Firstly, we compared a
group of insomniacs (n = 986) with another one free of
sleep complaints (n = 584). Secondly, all subjects suffer-
ing from mood and organic sleep complaints (snoring and
nocturnal periodic leg movements) were excluded.
RESULTS: In the non-adjusted by mood and organic
sleep complaints comparison (n = 986) we found a higher
absenteeism than in insomniac group than in control (9.6
+/- 31 days versus 5.8 +/- 19 days, U Mann-Withney, 
p < 0.01). However, no differences (6.39 vs. 6.02 days, 
U Mann-Withney, p = NS) in absenteeism between the
control group and insomniacs free of depression or
organic sleep complaints were observed. Nevertheless,
insomniacs (complaining or not of mood or organic sleep
complaints) showed a poorer health status deﬁned by the
Nottingham Health Proﬁle than control subjects.
CONCLUSIONS: Insomniac complaints are strongly
associated with an alteration of quality of life. Absen-
teeism in insomniacs is related to associated mood 
disorders or organic sleep complaints.
NEUROLOGICAL/PAIN DISORDERS—Health
Policy Presentations
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OBJECTIVE: A French national epidemiological study 
on migraine was presented 10 years ago at the Migraine
trust. It was the ﬁrst study to cover an entire country
(HENRY P. et al.: Migraine prevalence in France. In New
advances in headache research: 2. Ed. Clifford Rose 1991
Smith Gordon-pp.: 11–14). This study has provided also
data on the burden of migraine in terms of its economic
and social impact. We would like today to update the
data.
METHODS: 1486 persons, aged over 15 and suffering
from headaches were randomly selected from a large 
representative sample of the French population. They
were asked to complete a questionnaire, which allowed 
discriminating sufferers of migraine according to IHS 
criteria.
RESULTS: Among the 1486 headache sufferers, we ﬁnd
880 migrainous people (1-1, 1-2 and 1-7 IHS criteria),
454 without migrainous headache and 152 with chronic
daily headache. If we compare the results of the certain
migraine group (1-1 and 1-2 IHS) we ﬁnd that they are
identical (8.1% (1989) versus 8.2% (1999)). However, if
we include the migrainous disorder group fulﬁlling all 
criteria but one (1-7 IHS), the prevalence rate for
migraine headache in France between 1989 and 1999
seems to show a clear increase, rising from 12.1% to
17.3% because of less restrictive criteria than those
applied ten years ago. Regarding the prevalence in general
population for chronic daily headache the rate is around
3% with 1.8% for men and 3.9% for women in 1999.
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OBJECTIVES: To identify through retrospective analy-
sis the difference in Glatiramer Acetate (Copaxone®)
therapy compliance between participants associated with
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Caremark pharmacy delivery and other pharmacies for
an MS population.
METHODS: Participants in Caremark’s pharmacy claims
database were retrospectively analyzed for compliance on
Glatiramer Acetate therapy. We compared two pharmacy
delivery systems on therapy compliance, episode duration
and cost by delivery episode. Compliance was deﬁned as
the total days supplied over the total calendar days
elapsed. Episodes were deﬁned as continuous time 
periods where prescription and pharmacy delivery system
remained constant. Pharmacy was categorized as Care-
mark (CMX) or Non-Caremark (OTH). Descriptive
information on available MS related medical claim data
was compiled. Compliance and cost differences between
pharmacies were calculated and tested for statistical sig-
niﬁcance using a chi-square test. The study period encom-
passed 08/1998 through 12/2000.
RESULTS: 1516 participants (74.8% female, mean age
44.3 +/- 10.2 years) received Glatiramer Acetate pre-
scriptions from August 1998 through December 2000.
1706 delivery episodes were identiﬁed (CMX 74%, OTH
26%). Compliance to Glatiramer Acetate therapy was
93.2% (se 0.008) for Caremark episodes, and 84.2% (se
0.014) for OTH (p < 0.0001). The duration of drug
therapy regiment was longer (427.1 days, se 8.454) for
CMX episodes Vs OTH (384.6 days, se 16.591, p =
0.0142). Observation of the total health care costs per
participant (N = 39) was $22,523 for CMX, and $81,707
for OTH.
CONCLUSION: Caremark specialty pharmacy services
were associated with higher compliance rates and longer
length of continuous therapy than alternate pharmacy
distribution channels. Though the cost of higher rates of
compliance also increases the pharmacy spend, the total
healthcare costs may be reduced by the maintenance of
increased compliance.
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OBJECTIVES: To assess utilization characteristics of
triptan medications (sumatriptan, naratriptan, zolmitrip-
tan and rizatriptan) and evaluate the need for migraine
quality improvement programs in a managed care 
population.
METHODS: Utilizing a pharmacy claim database from 
a managed care healthplan (over 1.9 million members),
patients who have at least one triptan claim during July
1, 1998–May 31, 2001 were identiﬁed. Patients were
included if continuously enrolled for 12 months follow-
ing the ﬁrst triptan prescription and did not have a triptan
claim during the previous six months. Patients receiving
two or more different triptans within a 3-day period were
considered concurrent triptan users. In order to stan-
dardize the quantity of triptan medication consumed per
patient across the different triptans, “headache equiva-
lents” (HE) were calculated for each medication by divid-
ing the quantity consumed by the maximum quantity
recommended for one headache. The number of patients
exceeding the recommended maximum consumption of 3
HE per month (36 HE per year) was determined.
RESULTS: A total of 5,294 new triptan users were 
identiﬁed. Of these, 39% received only one triptan pre-
scription during the follow-up period, accounting for
11% of the total triptan drug costs. Fifteen percent of the
patients required more than one unique triptan medica-
tion and 4% concurrently used two or more triptans
during the study period. Eight percent exceeded the rec-
ommended maximum consumption of 36 HE per year
and were responsible for 39% of the total triptan 
expenditures.
CONCLUSIONS: A notable number of patients received
only one triptan prescription. A small percentage of
patients received quantities exceeding recommendations
and accounted for a large portion of the triptan pharmacy
costs. Migraine quality improvement programs in these
subsets of patients may be valuable.
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OBJECTIVES: VA (Veteran’s Health Administration)
Cooperative studies convincingly demonstrate that
despite equal efﬁcacy, phenobarbital and phenytoin are
more likely to cause adverse effects, and an expert 
panel recommended carbamazepine as the drug of choice
for adult-onset seizures, with newer medications (lamot-
rigine, gabapentin) being preferable for treating elderly
epileptics. This study examines the state of AED use in
the VA during 1999.
METHODS: We linked administrative (FY1997-FY1999)
and pharmacy databases to identify veterans with
epilepsy who were on anti-epileptic drugs (AEDs, N =
63,853). We used logistic regression to determine if age
(>65 vs. <65) or type of care (primary care or primary
care and neurology) predicted use of: phenobarbital,
phenytoin, carbamazepine, and gabapentin. We con-
trolled for demographics, year diagnosed (1997 or before,
1998, 1999), seizure type (partial, generalized, both), and
number of epilepsy hospitalizations or emergency visits
(severity).
RESULTS: In 1999 patients were on: phenytoin 59%,
phenobarbital 10%, carbamazepine 20%, gabapentin
12%, lamotrigine 2%. Logistic regression indicated that
when year diagnosed, sex, race, and severity were con-
trolled, veterans under 65 were less likely to receive 
phenobarbital (OR .52–.56) and phenytoin (OR .46–
.49), and more likely to receive carbamazepine (OR
